Anthropic has drafted a new AI safety bill proposing government regulation to block AI models that pose "foreseeable, imminent risks" such as causing over 50 deaths or a billion dollars in property damage. The bill suggests using independent evaluators registered with the Commerce Department to assess AI risks, with a 72-hour window to alert authorities if catastrophic risks are found. This approach aims to create a voluntary but structured oversight system, contrasting with some industry leaders who oppose new laws. The proposal reflects growing concerns about AI safety and the need for clearer regulatory frameworks amid rising AI risks.
Anthropic's AI safety bill proposal is presented here alongside Pluang's Technology-sector market data for context. For readers following Technology stocks, here is Pluang's market snapshot as of Oct 21, 2026 04:41 WIB: out of 150 priced stocks, 123 rose and 25 fell. Among notable movers, VNET rose 5.80% with 100% buy orders and a typical hold time of 17 days, GPRO increased 5.77% with a nearly even buy-sell split and a hold time of 45 days, while IT gained 5.72% with 100% buy orders and a longer hold time of 65 days.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
